Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| AX0401 | Other Identifier | Company Internal | |
| 11828 | Other Identifier | Company Internal | |
| 12206 | Other Identifier | Company Internal | |
| 12214 | Other Identifier | Company Internal | |
| 12234 | Other Identifier | Company Internal | |
| 12213 | Other Identifier | Company Internal | |
| 12212 | Other Identifier | Company Internal | |
| 12216 | Other Identifier | Company Internal | |
| 12220 | Other Identifier | Company Internal | |
| 12219 | Other Identifier | Company Internal | |
| 12217 | Other Identifier | Company Internal | |
| 12225 | Other Identifier | Company Internal | |
| 12223 | Other Identifier | Company Internal | |
| 12229 | Other Identifier | Company Internal | |
| 12221 | Other Identifier | Company Internal | |
| 12218 | Other Identifier | Company Internal | |
| 12222 | Other Identifier | Company Internal | |
| 12230 | Other Identifier | Company Internal | |
| 12211 | Other Identifier | Company Internal | |
| 12227 | Other Identifier | Company Internal | |
| 12228 | Other Identifier | Company Internal | |
| 12226 | Other Identifier | Company Internal | |
| 12235 | Other Identifier | Company Internal | |
| 12233 | Other Identifier | Company Internal | |
| 12224 | Other Identifier | Company Internal | |
| 12215 | Other Identifier | Company Internal | |
| 12231 | Other Identifier | Company Internal | |
| 12232 | Other Identifier | Company Internal |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The observation period for each patient covered an initial treatment period with Avelox® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit (baseline) and at least one short-term follow-up visit (=initial treatment period).Optionally, long-term follow-ups (6 and 12 months) were documented, and a patient questionnaire was filled in.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Moxifloxacin (Avelox, BAY12-8039) | Drug | AECB patients under daily life treatment receiving moxifloxacin according to the local product information. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of impact of AECB on the patient and the community as well as effect and safety of a treatment with moxifloxacin tablets in daily life clinical practice | During documentation at baseline and at at least one short-term follow-up visit; at maximum two short-term (within ca. 14 days) and two long-term follow-up visits (after ca. 6 and 12 months). |
| Measure | Description | Time Frame |
|---|---|---|
| Course of symptom relief | During documentation of up to two short-term follow-up visits (within ca. 14 days) | |
| Speed of return to normal daily life activities | During documentation of the last short-term follow-up visit (after ca. 14 days) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with a diagnosis of AECB who take moxifloxacin
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Many Locations | Austria | |||||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 22749710 | Result | Anzueto A, Miravitlles M, Ewig S, Legnani D, Heldner S, Stauch K. Identifying patients at risk of late recovery (>/= 8 days) from acute exacerbation of chronic bronchitis and COPD. Respir Med. 2012 Sep;106(9):1258-67. doi: 10.1016/j.rmed.2012.06.002. Epub 2012 Jun 30. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Adverse events collection | Throughout the entire study, whenever Adverse Events occur |
| Evaluation of frequency of new exacerbations | During documentation of up to two long-term follow-up visits (after ca. 6 and 12 months) |
| Progression of chronic respiratory disease | During documentation of up to two long-term follow-up visits (after ca. 6 and 12 months) |
| Many Locations |
| Brazil |
| Many Locations | China |
| Many Locations | Colombia |
| Many Locations | Croatia |
| Many Locations | Egypt |
| Many Locations | El Salvador |
| Many Locations | Germany |
| Many Locations | Hong Kong |
| Many Locations | Hungary |
| Many Locations | Indonesia |
| Many Locations | Malaysia |
| Many Locations | Mexico |
| Many Locations | Morocco |
| Many Locations | Netherlands |
| Many Locations | Pakistan |
| Many Locations | Philippines |
| Many Locations | Poland |
| Many Locations | Singapore |
| Many Locations | Slovenia |
| Many Locations | South Korea |
| Many Locations | Switzerland |
| Many Locations | Taiwan |
| Many Locations | Turkey (Türkiye) |
| ID | Term |
|---|---|
| D029481 | Bronchitis, Chronic |
| D001982 | Bronchial Diseases |
| ID | Term |
|---|---|
| D001991 | Bronchitis |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D029424 | Pulmonary Disease, Chronic Obstructive |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077266 | Moxifloxacin |
| ID | Term |
|---|---|
| D024841 | Fluoroquinolones |
| D042462 | 4-Quinolones |
| D015363 | Quinolones |
| D011804 | Quinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided